Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
HNSCC
m6A regulators
oncogenes
poor prognosis
tumorigenesis
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
07
2020
accepted:
16
11
2020
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Genetic alterations in N6-methyladenosine (m6A) regulatory genes are observed in many cancers. Recent studies have shown that newly identified m6A regulatory gene family (IGF2BPs; IGF2BP1, IGF2BP2, and IGF2BP3) were highly expressed in various types of cancer that stabilize and promote translation of multiple oncogenes, resulting in tumor development, survival and drug resistance. However, the oncogenic roles and prognostic values of IGF2BPs in head and neck squamous cell carcinoma (HNSCC) remain largely unknown. In this study, we examined the m6A regulatory genes alteration, their mRNAs expression and the prognostic values in HNSCC. We also analyzed the interaction network and functional enrichment of m6A regulators. Our results showed that m6A regulatory genes were altered in 41% (205/504) of HNSCC patients, of which
Types de publication
Journal Article
Langues
eng
Pagination
3688-3697Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Cancer Cell. 2017 Jan 9;31(1):35-49
pubmed: 28041841
J Proteomics. 2018 Jan 16;171:87-94
pubmed: 28782718
J Clin Med. 2019 Nov 07;8(11):
pubmed: 31703248
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244981
Mol Cancer. 2020 May 12;19(1):88
pubmed: 32398132
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Cell Rep. 2018 Oct 30;25(5):1332-1345.e5
pubmed: 30380422
Front Mol Biosci. 2020 Apr 24;7:68
pubmed: 32391379
Mol Cancer. 2019 Dec 4;18(1):176
pubmed: 31801551
Mol Ther Nucleic Acids. 2020 Jun 5;20:1-12
pubmed: 32145676
Nat Cell Biol. 2018 Mar;20(3):285-295
pubmed: 29476152
J Mol Neurosci. 2016 Oct;60(2):131-6
pubmed: 27370540
Clin Cancer Res. 2017 Mar 15;23(6):1379-1387
pubmed: 28039268
J Exp Clin Cancer Res. 2019 Dec 18;38(1):497
pubmed: 31852504
J Hematol Oncol. 2017 Feb 2;10(1):39
pubmed: 28153030
Cell Death Dis. 2018 Jan 26;9(2):124
pubmed: 29374143
Semin Cancer Biol. 2014 Dec;29:3-12
pubmed: 25068994
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Cell Mol Immunol. 2020 May;17(5):550-551
pubmed: 31649306
Front Genet. 2018 Feb 02;9:2
pubmed: 29456550
Cell Mol Immunol. 2020 Jun;17(6):668-669
pubmed: 32152551
Cancer Res. 2019 Apr 1;79(7):1285-1292
pubmed: 30894375
Sci Rep. 2017 May 22;7(1):2229
pubmed: 28533522
Protein Sci. 2018 Jan;27(1):233-244
pubmed: 28940711
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
PLoS One. 2012;7(8):e43265
pubmed: 22912841
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Biomark. 2018;21(4):859-868
pubmed: 29439311
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Mol Cancer. 2019 Jun 24;18(1):112
pubmed: 31230592
Am J Cancer Res. 2019 Oct 01;9(10):2156-2169
pubmed: 31720080
Mol Biol Rep. 2019 Jun;46(3):2693-2701
pubmed: 30805892
Aging (Albany NY). 2019 Mar 15;11(6):1633-1647
pubmed: 30877265